§
PatentCue
Patent Intelligence
Join Waitlist Sign In
← Back to Patent Explorer
US4533541A Expired / Lapsed US ⏱️ 0.0 years remaining

Tin-117m-labeled stannic (Sn4+) chelates

Assignee: United States, ENERGY THE, Secretary of, Department of
•
Filing: 1983-08-25
•
Granted: 1985-08-06
•
Expires: 2003-08-25
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The radiopharmaceutical reagents of this invention and the class of Tin-117m radiopharmaceuticals are therapeutic and diagnostic agents that incorporate gamma-emitting nuclides that localize in bone after intravenous injection in mammals (mice, rats, dogs, and rabbits). Images reflecting bone structure or function can then be obtained by a scintillation camera that detects the distribution of ionizing radiation emitted by the radioactive agent. Tin-117m-labeled chelates of stannic tin localize almost exclusively in cortical bone. Upon intravenous injection of the reagent, the preferred chelates are phosphonate compounds, preferable, PYP, MDP, EHDP, and DTPA. This class of reagents is therapeutically and diagnostically useful in skeletal scintigraphy and for the radiotherapy of bone tumors and other disorders.

Inventors

  • 👤 Suresh C. Srivastava
  • 👤 George E. Meinken
  • 👤 Powell Richards

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-29 19:18
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/0489; A61K51/0474; A61K51/0478; C; C07; C07C; C07C59/00; C07F; C07F7/00; C07F7/22; C07F7/2208; A61K2121/00; A61K2123/00

Claims Analysis

Total Claims: 10
Claim 1
Independent Claim 36 words
A radiopharmaceutical composition consisting of Tin-117m-labeled Stannic (Sn 4+ )-chelate in which the chelate component is a chelant selected from the group consistency of methylene diphosphonate (MDP), pyrophosphate (PYP), ethylidenehydroxydisodium phosphonate (EHDP) and diethylinetriaminopentaacetic acid (DTPA).
Claim 2
Dependent Claim 36 words
A radiopharmaceutical composition consisting of Tin-117m-labeled Stannic (Sn 4+ )-chelate in which the chelate component is a chelant selected from the group consistency of methylene diphosphonate (MDP), pyrophosphate (PYP), ethylidenehydroxydisodium phosphonate (EHDP) and diethylinetriaminopentaacetic acid (DTPA).
Claim 3
Dependent Claim 9 words
A radiopharmaceutical composition consisting of tin-117m-Stannic (Sn 4+ )-DTPA.
Claim 4
Dependent Claim 9 words
A radiopharmaceutical composition consisting of tin-117m-Stannic (Sn 4+ )-DTPA.
Claim 5
Independent Claim 26 words
A method of preparing bone for scintigraphical analysis consisting of administering a scintigraphically acceptable amount of chelate tagged with tin-117m in Stannic (Sn 4+ ) form.
Claim 6
Independent Claim 26 words
A method of preparing bone for scintigraphical analysis consisting of administering a scintigraphically acceptable amount of chelate tagged with tin-117m in Stannic (Sn 4+ ) form.
Claim 7
Independent Claim 28 words
A method for radiopharmaceutical skeletal imaging comprising administering intravenously tin-117m-labeled Stannic (Sn +4 ) chelate reagent and detecting the tin-117m by gamma scintigraphy or a whole body scan.
Claim 8
Independent Claim 28 words
A method for radiopharmaceutical skeletal imaging comprising administering intravenously tin-117m-labeled Stannic (Sn +4 ) chelate reagent and detecting the tin-117m by gamma scintigraphy or a whole body scan.
Claim 9
Independent Claim 36 words
A method of monitoring a mammalian skeletal system comprising intravenously administering a tin-117m-labeled Stannic (Sn 4+ ) chelate reagent and measuring by scintigraphy the distribution of the chelate throughout the body and its localization on bone.
Claim 10
Independent Claim 36 words
A method of monitoring a mammalian skeletal system comprising intravenously administering a tin-117m-labeled Stannic (Sn 4+ ) chelate reagent and measuring by scintigraphy the distribution of the chelate throughout the body and its localization on bone.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1988-08-05 1989-02-04 1989-08-06 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1992-08-05 1993-02-04 1993-08-06 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1996-08-05 1997-02-04 1997-08-06 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag